1MRNA Stock Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$114.48 |
52 Week High | US$124.26 |
52 Week Low | US$68.00 |
Beta | 1.59 |
1 Month Change | 19.71% |
3 Month Change | 27.92% |
1 Year Change | -6.53% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -13.89% |
Recent News & Updates
Recent updates
Shareholder Returns
1MRNA | IT Biotechs | IT Market | |
---|---|---|---|
7D | 14.5% | 2.8% | -1.7% |
1Y | -6.5% | -10.6% | 17.4% |
Return vs Industry: 1MRNA exceeded the Italian Biotechs industry which returned -10.4% over the past year.
Return vs Market: 1MRNA underperformed the Italian Market which returned 20.4% over the past year.
Price Volatility
1MRNA volatility | |
---|---|
1MRNA Average Weekly Movement | 7.6% |
Biotechs Industry Average Movement | 7.6% |
Market Average Movement | 4.4% |
10% most volatile stocks in IT Market | 7.7% |
10% least volatile stocks in IT Market | 2.8% |
Stable Share Price: 1MRNA's share price has been volatile over the past 3 months.
Volatility Over Time: 1MRNA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
1MRNA fundamental statistics | |
---|---|
Market cap | €44.67b |
Earnings (TTM) | -€5.54b |
Revenue (TTM) | €4.79b |
9.3x
P/S Ratio-8.0x
P/E RatioIs 1MRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1MRNA income statement (TTM) | |
---|---|
Revenue | US$5.15b |
Cost of Revenue | US$8.77b |
Gross Profit | -US$3.62b |
Other Expenses | US$2.35b |
Earnings | -US$5.97b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -15.59 |
Gross Margin | -70.27% |
Net Profit Margin | -115.82% |
Debt/Equity Ratio | 0% |
How did 1MRNA perform over the long term?
See historical performance and comparison